Jasper Therapeutics 10-Q Flags Going Concern Risk Despite $132M Kira Merger Financing
JSPR has more than doubled off its 52-week low of $0.315 on light trading volume (0.1× avg).
Summary
Jasper Therapeutics' first post-merger 10-Q reiterates going concern doubts, discloses a $30M CVR tied to briquilimab's FDA voucher, and reveals a Nasdaq delisting risk with a November 30 deadline.
Key Events · Earnings and Guidance · JSPR
-
Going Concern Warning Reiterated
Substantial doubt about the company's ability to continue as a going concern is stated in the 10-Q, driven by a potential obligation to repurchase Non-Voting Convertible Preferred Stock if stockholder approval for conversion is not obtained within 12 months.
-
Cash Position and PIPE Proceeds
Cash and cash equivalents were $7.3 million as of June 30, 2026. The $132.0 million PIPE financing closed on July 20, 2026, providing near-term runway but not eliminating the going concern risk.
-
Nasdaq Delisting Risk
A Nasdaq deficiency notice was received on June 3, 2026 for failing to maintain a $1.00 minimum bid price. The company has until November 30, 2026 to regain compliance, with a reverse stock split as a possible remedy.
-
Contingent Value Rights (CVR)
Each pre-merger Jasper shareholder received one CVR entitling them to a pro rata share of $30.0 million if the FDA issues a Priority Review Voucher for briquilimab by December 31, 2028.
Analysis · JSPR · Life Sciences
The first quarterly report following the Kira Pharmaceuticals merger and $132 million PIPE financing has been filed by Jasper Therapeutics. A going concern warning is reiterated in the 10-Q, citing the potential obligation to repurchase the Non-Voting Convertible Preferred Stock if stockholders do not approve conversion within 12 months. Only $7.3 million in cash was on hand as of June 30, 2026, before the PIPE proceeds arrived on July 20. The filing also discloses a $30 million contingent value right tied to an FDA priority review voucher for briquilimab, a new Mirador license agreement with up to $458.5 million in potential milestone payments, and a Nasdaq minimum bid price deficiency with a November 30, 2026 compliance deadline. These details materially expand on the merger announcement and highlight significant liquidity and listing risks.
At the time of this filing, JSPR was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.5M. The 52-week trading range was $0.32 to $3.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.